Ads by Google

Drug Clinical Trials

R7128 Achieves 85% Rapid Virologic Response For Chronic Hepatitis C Treatment

Pharmasset announces the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected with hepatitis C virus genotype 1.

Health and Wellness: 

R1507 Antibody To Enter Phase II Study To Treat Sarcoma

Roche has initiated a Phase II clinical study of R1507 for the treatment of recurrent or refractory sarcoma. The R1507 antibody was created by Genmab under the company's agreement with Roche and initiation of the trial will trigger a milestone payment to Genmab of USD 500,000.

"R1507 will be the first antibody created by Genmab under our agreement with Roche to enter Phase II development," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that R1507 may offer an additional treatment option to sarcoma patients."

About Sarcoma

Health and Wellness: 

Amicus Announces Positive Results From Clinical Trials Of Amigal For Fabry Disease

Amicus Therapeutics announced positive results from its recently completed Phase 2 clinical trials of Amigal (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

Health and Wellness: 

Innocoll Initiates Clinical Trial To Investigate CollaRx For Treatment Of Mildly Infected Diabetic Foot Ulcers

Innocoll announced that the first of three planned phase 2 clinical trials for the treatment and prevention of infected diabetic foot ulcers, has commenced dosing.

Health and Wellness: 

SuperGen Initiates Clinical Trial Of Novel Tyrosine Kinase Inhibitor

SuperGen has dosed the first patient in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan, and erlotinib. The trial is expected to enroll up to 105 patients at five study centers.

Health and Wellness: 

Pages